2022-02-21
One of the most important scientific achievements of Polish researchers in recent years is the result of research on regulatory T cells, or Tregs, and their pioneering use in the cell therapy of hazardous autoimmune diseases, including type 1 diabetes. By administering regulatory cells, we are able to delay its development, said Prof. Piotr Trzonkowski in Program 1 of Polskie Radio.
The broadcast recording is available for listening on the website:
2024-11-14
PolTREG received a new patent from China for anti-gen specific Tregs cellular therapy
2024-09-26
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
2024-09-09
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
2024-07-24
The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.
